The three costliest therapies under Medicare health insurance in the United States saw price hikes in 2020 but there was not enough evidence of new clinical benefits, the Institute for Clinical and Economic Review (ICER) said on Tuesday.
https://www.pharmalive.com/wp-content/uploads/2022/12/Reuterspillpackets.jpg607960Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-12-06 08:09:232022-12-06 09:00:10Price hikes for some Medicare therapies unsupported by clinical benefits data – Report
